COR
Cencora, Inc.
$318.02
장중 · Vol 17.2K · 52주 $244.82–$377.54 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $320.02 · Aug 31, 2026
COR 가격 추세
종가
$320.02
시가
$322.30
고가
$320.86
저가
$319.04
30초 브리핑
COR 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 55%
52주 범위 중간 구간으로 가격 위치만으로 방향성은 제한적입니다.
Forward P/E 16.4배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 0.7배
거래 참여가 낮아 현재 움직임의 신뢰도가 제한적입니다.
2026-11-04
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
COR 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
1 West First Avenue · Conshohocken, PA, United States · 직원 47,000명
시가총액
$61.75B
Trailing P/E
23.9
최근 12개월 이익 기준
Forward P/E
16.4
이익 증가 기대 반영
EPS (TTM)
$13.46
배당 수익률
0.75%
배당성향
17.4%
베타
0.57
시장보다 방어적
ROE
96.9%
P/B
20.24
EV/EBITDA
13.2
52주 범위
$244.82 – $377.54
현재 위치 55%
거래량
622.9K
20일 평균 948.1K · 0.7배
애널리스트 의견
매수 80%
총 15명 · 0m
DITM LEAPS Analysis
COR 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| COR280121C00175000 | 1/21/28 · 1.4Y | $175.00 | $158.50 | 1.9x | 0.9188 | 6.3% | 3.15% | 52.95% | 5 | 80.23 | |
| COR270917C00190000 | 9/17/27 · 1.0Y | $190.00 | $141.75 | 2.1x | 0.9140 | 5.8% | 3.17% | 51.42% | 5 | 79.49 | |
| COR280121C00185000 | 1/21/28 · 1.4Y | $185.00 | $149.75 | 2.0x | 0.9098 | 7.5% | 3.01% | 50.67% | 1 | 77.41 | |
| COR280121C00290000 | 1/21/28 · 1.4Y | $290.00 | $43.50 | 6.1x | 0.8259 | 22.8% | 9.20% | 17.49% | 24 | 76.36 | |
| COR270917C00210000 | 9/17/27 · 1.0Y | $210.00 | $124.25 | 2.3x | 0.8901 | 8.6% | 3.62% | 47.72% | 5 | 75.84 | |
| COR280121C00210000 | 1/21/28 · 1.4Y | $210.00 | $128.50 | 2.2x | 0.8813 | 11.6% | 3.11% | 46.17% | 0 | 72.96 | |
| COR280121C00220000 | 1/21/28 · 1.4Y | $220.00 | $120.25 | 2.3x | 0.8669 | 13.8% | 3.74% | 44.93% | 1 | 70.34 | |
| COR280121C00230000 | 1/21/28 · 1.4Y | $230.00 | $112.00 | 2.5x | 0.8531 | 16.4% | 3.57% | 43.05% | 9 | 70.33 | |
| COR280121C00240000 | 1/21/28 · 1.4Y | $240.00 | $104.50 | 2.6x | 0.8356 | 20.0% | 3.83% | 42.08% | 14 | 67.37 | |
| COR280121C00250000 | 1/21/28 · 1.4Y | $250.00 | $96.50 | 2.7x | 0.8174 | 23.7% | 5.18% | 40.96% | 5 | 62.60 | |
| COR280121C00260000 | 1/21/28 · 1.4Y | $260.00 | $89.25 | 2.9x | 0.7982 | 28.7% | 5.04% | 39.69% | 17 | 59.93 | |
| COR280121C00270000 | 1/21/28 · 1.4Y | $270.00 | $82.00 | 3.1x | 0.7779 | 34.6% | 4.88% | 38.31% | 19 | 55.77 | |
| COR280121C00280000 | 1/21/28 · 1.4Y | $280.00 | $75.25 | 3.3x | 0.7547 | 42.1% | 5.98% | 37.57% | 18 | 49.94 |
재무제표
COR 연간 손익·현금흐름·재무상태
매출 성장률
+9.3%
최근 연간 YoY
EPS 성장률
+5.7%
최근 연간 YoY
영업이익률
1.2%
최근 연간
FCF 마진
1.0%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $321.33B+9.3% | $293.96B+12.1% | $262.17B+9.9% | $238.59B |
| 매출총이익 | $11.48B+15.8% | $9.91B+10.6% | $8.96B+8.0% | $8.30B |
| 영업이익 | $3.93B+24.6% | $3.16B+17.6% | $2.69B-2.5% | $2.75B |
| 순이익 | $1.55B+3.0% | $1.51B-13.5% | $1.75B+2.7% | $1.70B |
| 희석 EPS | $7.96+5.7% | $7.53-11.7% | $8.53+6.1% | $8.04 |
| EBITDA | $3.75B+11.1% | $3.37B+0.0% | $3.37B+8.6% | $3.10B |
| 영업현금흐름 | $3.88B+11.2% | $3.48B-10.9% | $3.91B+44.7% | $2.70B |
| 잉여현금흐름 | $3.21B+7.0% | $3.00B-13.2% | $3.45B+56.5% | $2.21B |
| 총자산 | $76.59B+14.1% | $67.10B+7.3% | $62.56B+10.6% | $56.56B |
| 총부채 | $7.66B+74.6% | $4.39B-8.3% | $4.79B-16.1% | $5.70B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
COR 실적·배당 일정
매출 하단
$86.69B
EPS 하단
$4.38
매출 상단
$92.69B
배당 지급일
2026-08-31
1일 전
실적 발표일
2026-11-04
D-64
EPS 상단
$4.62
매출 컨센서스
$88.53B
EPS 컨센서스
$4.54
배당락일
2026-08-14
18일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Aug 14, 2026 | $0.6000 |
| May 15, 2026 | $0.6000 |
| Feb 13, 2026 | $0.6000 |
| Nov 14, 2025 | $0.6000 |
| Aug 15, 2025 | $0.5500 |
| May 16, 2025 | $0.5500 |
| Feb 14, 2025 | $0.5500 |
| Nov 15, 2024 | $0.5500 |
뉴스
COR 관련 최신 기사
제품·기술Beat the Market the Zacks Way: Accelerant, Insight, General Mills in Focus
Accelerant, Shopify and Carpenter Technology delivered strong gains, while Zacks upgrades and model portfolios spotlight key performers.
Zacks · Aug 31, 2026
실적AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.
Motley Fool · Aug 29, 2026
- 실적
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
Motley Fool · Aug 29, 2026
실적McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate
McKesson raises fiscal 2027 EPS guidance as oncology, GLP-1 volumes and specialty distribution drive faster profit growth despite cash-flow pressure.
Zacks · Aug 24, 2026
- 실적
Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?
McKesson's double-digit earnings growth, specialty expansion and capital returns support the story, but a premium valuation leaves less room for error.
Zacks · Aug 24, 2026
- 실적
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.
Motley Fool · Aug 14, 2026
제품·기술Cencora (COR): Leveraging Healthcare Growth and AI-Driven Productivity
Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% […]
Insider Monkey · Aug 14, 2026
실적5 Insightful Analyst Questions From Cencora’s Q2 Earnings Call
Cencora’s second quarter was marked by performance that met Wall Street’s expectations on revenue and exceeded consensus on non-GAAP profitability, driving a positive market response. Management credited execution in specialty pharmaceuticals, especially through its Management Services Organizations (MSOs) like OneOncology and RCA, as a core driver of growth, while digital transformation initiatives improved operational efficiency. CEO Robert Mauch highlighted the company’s unique positioning in
StockStory · Aug 14, 2026
일반US Stock Market Today: S&P 500 Futures Edge Up As Traders Eye Key CPI
The Morning Bull - US Market Morning Update Thursday, Aug, 13 2026 US stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up about 0.2% and Nasdaq-100 futures ahead by roughly 0.6%, as investors focus on a key inflation update and what it could mean for interest rates. July CPI is expected at 3.4% year on year, with core inflation seen at 2.5%, which would suggest the cost of living is still rising but closer to the central bank’s comfort zone. At the same...
Simply Wall St. · Aug 13, 2026
- 제품·기술
US Equity Markets End Mixed Amid Tech Stock Gains, Lower Inflation Data
US equity indexes ended mixed Wednesday amid stock gains by some major technology stocks and a four-
MT Newswires · Aug 12, 2026
홀더
COR 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
99.6%
기관 보유 (유동주식)
104.1%
내부자 보유
4.3%
기관 수
1,867
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 18.21M | $5.89B | 9.5% | -8.7% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 12.38M | $4.01B | 6.5% | 0.5% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 9.61M | $3.11B | 5.0% | 0.2% | Jun 30, 2026 |
| State Street Corporation | 9.27M | $3.00B | 4.9% | 0.9% | Jun 30, 2026 |
| T. Rowe Price Investment Management, Inc. | 7.41M | $2.40B | 3.9% | 17.7% | Jun 30, 2026 |
| Price (T.Rowe) Associates Inc | 7.13M | $2.31B | 3.7% | -2.6% | Jun 30, 2026 |
| JPMORGAN CHASE & CO | 5.94M | $1.92B | 3.1% | 21.7% | Jun 30, 2026 |
| Geode Capital Management, LLC | 5.45M | $1.77B | 2.9% | -2.0% | Jun 30, 2026 |
| Boston Partners | 4.87M | $1.58B | 2.5% | 8.6% | Jun 30, 2026 |
| Wellington Management Group, LLP | 4.56M | $1.48B | 2.4% | 0.3% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.